TY - JOUR
T1 - Impact of different vehicles for laser-assisted drug permeation via skin
T2 - Full-surface versus fractional ablation
AU - Lee, Woan Ruoh
AU - Shen, Shing Chuan
AU - Aljuffali, Ibrahim A.
AU - Li, Yi Ching
AU - Fang, Jia You
PY - 2014/2
Y1 - 2014/2
N2 - Purpose: This study aimed to assess impact of different vehicles for laser-assisted skin drug delivery. We also tried to uncover the mechanisms by which different vehicles affect laser-aided skin permeation. Methods: Full-surface ablative (conventional) and fractional lasers were used to irradiate nude mouse skin. Imiquimod and 5-aminolevulinic acid (ALA) were used as lipophilic and hydrophilic permeants. Vehicles employed included water with 40% polyethylene glycol 400 (PEG 400), propylene glycol (PG), and ethanol. Lipid nanoparticles were also utilized as carriers. Results: In vitro permeation profiles showed improvement in imiquimod flux with conventional laser (2.5 J/cm2) producing a 12-, 9-, and 5-fold increase when loading imiquimod in 40% PEG400, PG, and ethanol, respectively, as compared with intact skin. Nanoparticulate delivery by laser produced a 6-fold enhancement in permeation. Fractional laser produced less enhancement of imiquimod delivery than conventional laser. Laser exposure increased follicular imiquimod accumulation from 0.80 to 5.81 μg/cm2. ALA permeation from aqueous buffer, PEG 400, and PG with conventional laser treatment was 641-, 445-, and 104-fold superior to passive control. In vivo skin deposition of topically applied ALA examined by confocal microscopy indicated the same trend as the in vitro experiment, with aqueous buffer showing the greatest proporphyllin IX signaling. Diffusion of cosolvent molecules into ablated skin and drug partitioning from vehicle to skin are two predominant factors controlling laser-assisted delivery. In contrast to conventional laser, lateral drug diffusion was anticipated for fractional laser. Conclusions: Our results suggest that different drug delivery vehicles substantially influence drug penetration enhanced by lasers.
AB - Purpose: This study aimed to assess impact of different vehicles for laser-assisted skin drug delivery. We also tried to uncover the mechanisms by which different vehicles affect laser-aided skin permeation. Methods: Full-surface ablative (conventional) and fractional lasers were used to irradiate nude mouse skin. Imiquimod and 5-aminolevulinic acid (ALA) were used as lipophilic and hydrophilic permeants. Vehicles employed included water with 40% polyethylene glycol 400 (PEG 400), propylene glycol (PG), and ethanol. Lipid nanoparticles were also utilized as carriers. Results: In vitro permeation profiles showed improvement in imiquimod flux with conventional laser (2.5 J/cm2) producing a 12-, 9-, and 5-fold increase when loading imiquimod in 40% PEG400, PG, and ethanol, respectively, as compared with intact skin. Nanoparticulate delivery by laser produced a 6-fold enhancement in permeation. Fractional laser produced less enhancement of imiquimod delivery than conventional laser. Laser exposure increased follicular imiquimod accumulation from 0.80 to 5.81 μg/cm2. ALA permeation from aqueous buffer, PEG 400, and PG with conventional laser treatment was 641-, 445-, and 104-fold superior to passive control. In vivo skin deposition of topically applied ALA examined by confocal microscopy indicated the same trend as the in vitro experiment, with aqueous buffer showing the greatest proporphyllin IX signaling. Diffusion of cosolvent molecules into ablated skin and drug partitioning from vehicle to skin are two predominant factors controlling laser-assisted delivery. In contrast to conventional laser, lateral drug diffusion was anticipated for fractional laser. Conclusions: Our results suggest that different drug delivery vehicles substantially influence drug penetration enhanced by lasers.
KW - 5-aminolevulinic acid
KW - ablative laser
KW - imiquimod
KW - nanoparticle
KW - vehicle
UR - http://www.scopus.com/inward/record.url?scp=84896719572&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896719572&partnerID=8YFLogxK
U2 - 10.1007/s11095-013-1167-4
DO - 10.1007/s11095-013-1167-4
M3 - Article
C2 - 24022680
AN - SCOPUS:84896719572
SN - 0724-8741
VL - 31
SP - 382
EP - 393
JO - Pharmaceutical Research
JF - Pharmaceutical Research
IS - 2
ER -